Capecitabine Tablet, Film Coated
Product Images NDC 0093-7474

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 0093-7474). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

Chemical structure diagram of Capecitabine, the active ingredient shown in the product data. The structural formula illustrates the molecular arrangement and bonds of the Capecitabine molecule.*

FDA Label Image

Image 2

An illustration showing the metabolic pathway of Capecitabine conversion. It depicts chemical structures of Capecitabine and its metabolites 5'-DFCR, 5'-DFUR, and 5-FU with arrows indicating enzymatic steps involving Carboxylesterase, Cyd deaminase, and dThdPase.*

FDA Label Image

Image 3

A survival curve graph comparing two treatment groups over time in months since randomization: Capecitabine and 5-FU + Leucovorin. The vertical axis represents survival probability, and the horizontal axis shows time in months, with survival decreasing over time for both groups. Patient risk numbers at different months are listed below the graph.*

FDA Label Image

Image 4

A survival curve chart comparing treatment groups for Capecitabine and 5-FU + Leucovorin over months since randomization. The X-axis represents time in months, and the Y-axis represents survival probability. The chart includes the number of patients at risk at various time points for each group.*

FDA Label Image

Image 5

Kaplan-Meier survival curve comparing estimated probability over time (in days) between two treatment groups: 5-FU + Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/sqm twice daily intermittent. The y-axis shows estimated probability from 0.0 to 1.0, and the x-axis represents time in days up to 1500.*

FDA Label Image

Image 6

A survival curve chart comparing estimated probability over time (days) for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks and Capecitabine 1250 mg/sqm twice daily with intermittent Docetaxel 75 mg/sqm every 3 weeks. The X-axis represents time in days, and the Y-axis represents estimated probability from 0 to 1. The Capecitabine group shows a higher survival probability over time compared to the Docetaxel group.*

FDA Label Image

Image 7

Kaplan-Meier plot illustrating estimated probability over time in days for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph compares survival or event-free probabilities over approximately 800 days.*

FDA Label Image

Image 8

Label for Capecitabine Tablets USP 150 mg, a cytotoxic agent. The label indicates the product is for prescription use only, with a package count of 60 film-coated tablets. The labeler is Teva Pharmaceuticals USA, Inc. Additional information includes storage instructions and safety warnings.*

FDA Label Image

Image 9

Capecitabine Tablets USP 500 mg film-coated tablets label from Teva Pharmaceuticals USA, Inc. The label indicates the product is a cytotoxic agent, supplied in a pack of 120 tablets. It includes storage instructions, dispensing warnings, and manufacturer details, with a prominent Teva logo and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.